Brought to you by 
BMS licenses anti-KIR antibody from Innate Pharma
05 Oct 2021
Executive Summary
Innate Pharma SA (oncology and anti-inflammatory therapeutics that target the activation of innate immune cells) has licensed Bristol-Myers Squibb Co. exclusive worldwide development, manufacturing, and marketing rights to its Phase I fully human monoclonal antibody IPH2102--a killer-cell immunoglobulin-like receptor (KIR) inhibitor--for cancer and all other potential therapeutic areas. BMS will also receive rights to additional KIR blockers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS licenses anti-KIR antibody from Innate Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice